Saquinavir
FDA-approved product (capsule, oral), marketed as Fortovase, Invirase.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- HIV infection
- HIV-1 infection
- Viral disease
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Protease inhibitors
- Anti-infective classification
- Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AE01
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA51.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli49.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae33.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis71.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Saquinavir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Trimetrexate GlucuronateExisting use: Other agents against amoebiasis and other protozoal diseases88.6% AI-predicted activityagainst E. coliLab records exist17 registered studies
- Folic AcidExisting use: Acne, Anemia, Anemia (phenotype) and 8 more87.0% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- MethotrexateExisting use: Acute lymphoblastic leukemia, Adenoma, Arthritis and 21 more86.8% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- PralatrexateExisting use: Cancer, Mature T-cell and NK-cell non-Hodgkin lymphoma, Neoplasm and 2 more82.2% AI-predicted activityagainst E. coli44 registered studies
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives81.0% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Leucovorin CalciumExisting use: Osteosarcoma67.6% AI-predicted activityagainst E. coli50+ registered studies
- LevoleucovorinExisting use: Anemia, Colorectal adenocarcinoma, Colorectal cancer and 3 more67.6% AI-predicted activityagainst E. coli50+ registered studies
- PyrimethamineExisting use: Malaria, Toxoplasmosis64.6% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Copanlisib DihydrochlorideExisting use: Follicular lymphoma, Neoplasm, Neoplasm of mature B-cells63.5% AI-predicted activityagainst E. coli10 registered studies
- AfamelanotideExisting use: Erythropoietic protoporphyria62.6% AI-predicted activityagainst E. coli23 registered studies
- Rimegepant SulfateExisting use: Migraine disorder61.6% AI-predicted activityagainst E. coli50+ registered studies
- Histrelin AcetateExisting use: Neoplasm, Prostate adenocarcinoma, Prostate cancer61.6% AI-predicted activityagainst E. coli13 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Interaction With HIV Antiretroviral Agents
NCT02556268 · start 2016-02-23
Registered record
- Registry ID
- NCT02556268
- Conditions
- HIV-DDI
- Interventions
- Riociguat (Adempas, BAY 63-2521); ATRIPLA; COMPLERA; STRIBILD; TRIUMEQ; Antiretroviral protease inhibitor
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2016-02-23
- Completion
- 2016-12-07
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV-DDIInterventionRiociguat (Adempas, BAY 63-2521); ATRIPLA; COMPLERA; STRIBILD +2 morePhasePhase 1Registry statusCompletedStudy to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I
NCT02616029 · start 2015-12-17
Registered record
- Registry ID
- NCT02616029
- Conditions
- HIV-1 Infection
- Interventions
- E/C/F/TAF
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2015-12-17
- Completion
- 2019-07-11
- Enrolment
- 66
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV-1 InfectionInterventionE/C/F/TAFPhasePhase 3Registry statusCompletedSafety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults
NCT02605954 · start 2015-11-18
Registered record
- Registry ID
- NCT02605954
- Conditions
- HIV-1 Infection
- Interventions
- E/C/F/TAF; ABC/3TC; Third Antiretroviral Agent
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2015-11-18
- Completion
- 2018-01-24
- Enrolment
- 275
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV-1 InfectionInterventionE/C/F/TAF; ABC/3TC; Third Antiretroviral AgentPhasePhase 3Registry statusCompletedTrial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy
NCT02302547 · start 2014-12
Registered record
- Registry ID
- NCT02302547
- Conditions
- HIV
- Interventions
- triple therapy; dual therapy
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2014-12
- Completion
- 2018-09-21
- Enrolment
- 224
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIVInterventiontriple therapy; dual therapyPhasePhase 3Registry statusCompletedStudy of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV
NCT02016924 · start 2014-01-16
Registered record
- Registry ID
- NCT02016924
- Conditions
- Acquired Immune Deficiency Syndrome (AIDS); HIV Infections
- Interventions
- ATV; DRV; Cobicistat; BR; F/TAF; LPV/r; Third Unboosted Drug; Cobicistat TOS; F/TAF TOS
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Active not recruiting
- Start
- 2014-01-16
- Completion
- 2027-03
- Enrolment
- 133
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcquired Immune Deficiency Syndrome (AIDS); HIV InfectionsInterventionATV; DRV; Cobicistat; BR +5 morePhasePhase 2 / Phase 3Registry statusActive not recruitingA Study of Ritonavir-Boosted Invirase (Saquinavir) in Treatment-Naïve HIV-1 Infected Patients
NCT01638650 · start 2012-01
Registered record
- Registry ID
- NCT01638650
- Conditions
- HIV Infections
- Interventions
- Nucleoside Reverse Transcriptase Inhibitor (NRTIs); ritonavir; saquinavir [Invirase]
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2012-01
- Completion
- 2012-06
- Enrolment
- 23
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionNucleoside Reverse Transcriptase Inhibitor (NRTIs); ritonavir; saquinavir [Invirase]PhasePhase 1Registry statusCompletedStudy to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF
NCT01252940 · start 2010-11
Registered record
- Registry ID
- NCT01252940
- Conditions
- HIV-1 Infection
- Interventions
- FTC/RPV/TDF; PI; RTV; NRTIs
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2010-11
- Completion
- 2014-10
- Enrolment
- 482
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV-1 InfectionInterventionFTC/RPV/TDF; PI; RTV; NRTIsPhasePhase 3Registry statusCompletedObservational Study on Predictors of Response to Invirase (Saquinavir) Treatment in Treatment-naïve Patients With HIV Infection
NCT01297127 · start 2010-08
Registered record
- Registry ID
- NCT01297127
- Conditions
- HIV Infections
- Interventions
- Not recorded
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2010-08
- Completion
- 2013-09
- Enrolment
- 151
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionNot recordedPhaseNot recordedRegistry statusCompletedPharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function
NCT00717067 · start 2008-07
Registered record
- Registry ID
- NCT00717067
- Conditions
- Human Immunodeficiency Virus (HIV) Infection
- Interventions
- Maraviroc; Maraviroc; Ritonavir; Saquinavir; Maraviroc; Ritonavir; Saquinavir; Maraviroc; Ritonavir; Saquinavir; Maraviroc; Maraviroc; Maraviroc
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2008-07
- Completion
- 2008-11
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHuman Immunodeficiency Virus (HIV) InfectionInterventionMaraviroc; Maraviroc; Ritonavir; Saquinavir +9 morePhasePhase 4Registry statusCompletedPharmacokinetics of Low Dose Ritonavir
NCT00622206 · start 2008-01
Registered record
- Registry ID
- NCT00622206
- Conditions
- HIV Infections
- Interventions
- ritonavir and saquinavir
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Completed
- Start
- 2008-01
- Completion
- 2008-08
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionritonavir and saquinavirPhasePhase 1 / Phase 2Registry statusCompletedClinical Trial of CNS-targeted HAART (CIT2)
NCT00624195 · start 2007-03
Registered record
- Registry ID
- NCT00624195
- Conditions
- HIV Infections
- Interventions
- FDA Approved Antiretroviral Therapy (see list below)
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Completed
- Start
- 2007-03
- Completion
- 2012-06
- Enrolment
- 59
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionFDA Approved Antiretroviral Therapy (see list below)PhasePhase 2 / Phase 3Registry statusCompletedA Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection.
NCT00435929 · start 2006-09
Registered record
- Registry ID
- NCT00435929
- Conditions
- HIV Infections
- Interventions
- Ritonavir; saquinavir [Invirase]
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2006-09
- Completion
- 2009-11
- Enrolment
- 16
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionRitonavir; saquinavir [Invirase]PhasePhase 1Registry statusCompletedBASIC: Boosted Atazanavir or Saquinavir Induced Lipid Changes
NCT00389402 · start 2006-07
Registered record
- Registry ID
- NCT00389402
- Conditions
- HIV Infections
- Interventions
- saquinavir/ritonavir; atazanavir/ritonavir
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2006-07
- Completion
- 2008-07
- Enrolment
- 120
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionsaquinavir/ritonavir; atazanavir/ritonavirPhasePhase 4Registry statusCompletedStudy of Genetic Polymorphisms in Thai HIV-1 Infected Patients on SQV/r
NCT00476502 · start 2006-02
Registered record
- Registry ID
- NCT00476502
- Conditions
- HIV Infections
- Interventions
- identify genetic polymorphism in Thai HIV infected
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2006-02
- Completion
- 2008-12
- Enrolment
- 250
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionidentify genetic polymorphism in Thai HIV infectedPhaseNot recordedRegistry statusCompletedDual Boosted Protease Inhibitor Regimens Without Any Additional Antiretroviral Therapy in HIV-1 Infected Patients (ANRS127)
NCT00122603 · start 2005-12
Registered record
- Registry ID
- NCT00122603
- Conditions
- HIV Infections
- Interventions
- Fosamprenavir; Saquinavir
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2005-12
- Completion
- 2007-08
- Enrolment
- 61
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionFosamprenavir; SaquinavirPhasePhase 2Registry statusCompleted